PT775142E - O6-benzilguaninas substituidas - Google Patents

O6-benzilguaninas substituidas

Info

Publication number
PT775142E
PT775142E PT95928237T PT95928237T PT775142E PT 775142 E PT775142 E PT 775142E PT 95928237 T PT95928237 T PT 95928237T PT 95928237 T PT95928237 T PT 95928237T PT 775142 E PT775142 E PT 775142E
Authority
PT
Portugal
Prior art keywords
mammal
compounds
aza
guanine
chem
Prior art date
Application number
PT95928237T
Other languages
English (en)
Portuguese (pt)
Inventor
Robert C Moschel
Anthony E Pegg
M Eileen Dolan
Mi-Young Chae
Original Assignee
Arch Dev Corp
Us Health
Penn State Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp, Us Health, Penn State Res Foundation Inc filed Critical Arch Dev Corp
Publication of PT775142E publication Critical patent/PT775142E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT95928237T 1994-08-01 1995-07-31 O6-benzilguaninas substituidas PT775142E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/283,953 US5525606A (en) 1994-08-01 1994-08-01 Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines

Publications (1)

Publication Number Publication Date
PT775142E true PT775142E (pt) 2002-04-29

Family

ID=23088285

Family Applications (2)

Application Number Title Priority Date Filing Date
PT95928237T PT775142E (pt) 1994-08-01 1995-07-31 O6-benzilguaninas substituidas
PT01108585T PT1142893E (pt) 1994-08-01 1995-07-31 6 (4) - benziloxipirimidinas substituidas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT01108585T PT1142893E (pt) 1994-08-01 1995-07-31 6 (4) - benziloxipirimidinas substituidas

Country Status (10)

Country Link
US (8) US5525606A (https=)
EP (3) EP1518854A1 (https=)
JP (2) JP3981407B2 (https=)
AT (2) ATE286054T1 (https=)
CA (2) CA2195856C (https=)
DE (2) DE69533900T2 (https=)
DK (2) DK0775142T3 (https=)
ES (2) ES2167451T3 (https=)
PT (2) PT775142E (https=)
WO (1) WO1996004281A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043228A (en) * 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EP1017394B1 (en) * 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6060458A (en) * 1998-02-13 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
US6677345B1 (en) * 1998-03-28 2004-01-13 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibitors
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
KR100368515B1 (ko) * 1999-02-03 2003-01-24 주식회사 엘지생명과학 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
AU2002216650A1 (en) 2000-10-31 2002-05-15 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
CN100439370C (zh) * 2001-02-08 2008-12-03 记忆药物公司 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
WO2003037860A2 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
AU2003261418B2 (en) * 2002-08-08 2010-05-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
DE10307928A1 (de) * 2003-02-25 2004-09-16 Faustus Forschungs Cie. Translational Cancer Research Gmbh Verwendung von 1-(2-Chlorethyl)-1-nitroso-3-(2-hydroxyethyl)-urea zur Behandlung von Pankreaskarzinomen, Weichteilsarkomen, Hodentumoren, Lymphomen, Thymomen, Wilms Tumoren, Nierenkarzinomen, Melanomen, Lungentumoren, intracerebralen Metastasen, Tumoren im Kopf- und Halsbereich, und Mamma-Karzinomen
MXPA06002997A (es) * 2003-09-18 2007-02-08 Conforma Therapeutics Corp Novedosos compuestos heterociclicos como inhibidores- hsp90.
WO2005068465A1 (en) * 2004-01-06 2005-07-28 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 2-amino-o4-substituted pteridines and their use as inactivators of o6-alkylguanine-dna alkyltransferase
US20080039321A1 (en) * 2004-05-12 2008-02-14 Bastiaans Henricus M Plant Growth Regulation
AU2005282562A1 (en) * 2004-09-08 2006-03-16 Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Beta-glucuronidase cleavable prodrugs of O6-alkylguanine-DNA alkyltransferase inactivators
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
AU2006230447A1 (en) * 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
US8178314B2 (en) * 2005-04-27 2012-05-15 Covalys Biosciences Ag Pyrimidines reacting with O6-alkylguanine-DNA alkyltransferase fusion protein and method for detecting protein
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
EP2700638A1 (en) * 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
WO2008137207A2 (en) * 2007-05-02 2008-11-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inactivators of o6-alkylguanine-dna alkyltransferase
EP1990661B1 (en) 2007-05-07 2018-08-15 CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Développement Isotropic zero-order diffractive filter
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
TR201908314T4 (tr) 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
KR101909711B1 (ko) 2009-05-06 2018-12-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120270812A1 (en) * 2009-08-24 2012-10-25 Duke University Compositions, methods, and kits for determining an alkyl transferase
CN101850504B (zh) * 2010-05-06 2011-11-16 陕西理工学院 一种用两个步进电机控制主轴运动的振动制孔装置
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
GB201106814D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
MX354412B (es) 2011-06-10 2018-03-05 Merck Patent Gmbh Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
US20130236504A1 (en) * 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
WO2014025749A2 (en) * 2012-08-06 2014-02-13 Sirga Advanced Biopharma, Inc. Small molecule inhibitors of viral protein interactions with human t-rna
EP3191486B1 (en) * 2014-09-11 2018-08-01 Bristol-Myers Squibb Company Thioether triazolopyridine and triazolopyrmidine inhibitors of myeloperoxidase
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IL64501A (en) * 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
EP0184473A1 (en) * 1984-10-26 1986-06-11 Merck & Co. Inc. Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives
US4801710A (en) * 1984-10-26 1989-01-31 Merck & Co., Inc. Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4965270A (en) * 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
US5723609A (en) * 1988-03-30 1998-03-03 E. R. Squibb & Sons, Inc. Bis (hydroxymethyl) cyclobutyl purines
US5352669A (en) * 1990-03-13 1994-10-04 The Of The United States Of America As Represented By The Department Of Health And Human Services O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity
US5091430A (en) * 1990-03-13 1992-02-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services O6 -substituted guanine compounds and methods for depleting O6 -alkylguanine-DNA alkyltransferase levels
US5691307A (en) * 1990-03-13 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services O6 -substituted guanine compositions and methods for depleting O6
EP0489878A1 (en) * 1990-06-29 1992-06-17 Vinamul Ltd. Emulsion polymerisation
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
HU217779B (hu) 1993-06-08 2000-04-28 Cancer Research Campaign Technology Limited O6-Helyettesített guaninszármazékok, ezeket tartalmazó gyógyászati készítmények, valamint eljárás e vegyületek előállítására
US6043228A (en) 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DK0648503T3 (da) 1993-09-22 2000-10-02 Hoechst Ag Pro-prodrugs, deres fremstilling og anvendelse
US5929046A (en) 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
EP0795334B1 (de) 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
US5965126A (en) 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
WO1999025386A1 (en) 1997-11-13 1999-05-27 Case Western Reserve University delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE

Also Published As

Publication number Publication date
DE69533900T2 (de) 2005-12-29
ATE286054T1 (de) 2005-01-15
JP2007077157A (ja) 2007-03-29
US5753668A (en) 1998-05-19
EP0775142A1 (en) 1997-05-28
EP1142893A1 (en) 2001-10-10
CA2632452A1 (en) 1996-02-15
US5525606A (en) 1996-06-11
DE69523462D1 (de) 2001-11-29
PT1142893E (pt) 2005-04-29
US6303604B1 (en) 2001-10-16
DE69533900D1 (de) 2005-02-03
DE69523462T2 (de) 2002-07-11
ES2233513T3 (es) 2005-06-16
ATE207490T1 (de) 2001-11-15
EP0775142B1 (en) 2001-10-24
CA2195856A1 (en) 1996-02-15
WO1996004281A1 (en) 1996-02-15
DK0775142T3 (da) 2002-02-18
EP1142893B1 (en) 2004-12-29
DK1142893T3 (da) 2005-03-29
ES2167451T3 (es) 2002-05-16
US6436945B2 (en) 2002-08-20
AU702711B2 (en) 1999-03-04
US6172070B1 (en) 2001-01-09
US6333331B1 (en) 2001-12-25
JP3981407B2 (ja) 2007-09-26
JPH10508288A (ja) 1998-08-18
CA2195856C (en) 2008-09-30
US5916894A (en) 1999-06-29
EP1518854A1 (en) 2005-03-30
US5958932A (en) 1999-09-28
US20020013299A1 (en) 2002-01-31
AU3207995A (en) 1996-03-04

Similar Documents

Publication Publication Date Title
PT1142893E (pt) 6 (4) - benziloxipirimidinas substituidas
BG103417A (en) Condensed pyrimidine bicyclic derivatives
PL300062A1 (en) Novel 7-(substituted)-8-(substituted)-9-[(substituted glycil) amido]-6-demethyl-6-deoxytetracyclines, methods of obtaining such compounds as well as their organic and inorganic salts and metal complex, pharmaceutical agent and veterinary agent
PL300063A1 (en) 7-(substituted)-9-[(substituted glycil) amido]-6-demethyl-6-deoxy-tetracyclines, methods of obtaining such compounds as well as their organic and inorganic salts and metal complex, pharmaceutical agent and veterinary agent
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
BR9805734A (pt) Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos.
ES2149305T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.
NO890567D0 (no) Anthracyklin-derivater.
IL123776A0 (en) Novel derivatives of cyclodepsipeptide PF 1022
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
ES8403910A1 (es) Procedimiento para la preparacion de nitratos de amino-deso-xi-1.4;3.6-dianhidro-hexito,asi como de sus sales de adicionacida farmacologicamente inocuas
ES2156633T3 (es) Derivados del acido tiazolidina-4-carboxilico como agentes citoprotectores.
GB8504072D0 (en) Cephem compounds
ES2102772T3 (es) Compuesto citotoxico y antiviral.
ATE148688T1 (de) Derivate des 5,6,7,9-tetrahydro-1,2,3-trimethoxy- 9-oxo-benzo(alpha)heptalens
KR970702869A (ko) 항종양성 인돌로피롤로카르바졸 유도체(antitumor indolopyprolocarbazole derivative)
IT1262565B (it) Disaccaridi di antracicline, loro processi di preparazione e composizioni farmaceutiche che li contengono.
DK0626383T3 (da) Palau'amin: Farmakologisk aktiv forbindelse fra en svamp
AR042571A1 (es) L-arabino disacaridos de antraciclinas, sus procesos de preparacion y composiciones farmaceuticas que los contienen y su uso para la preparacion de composisiones farmaceuticas
DE3365781D1 (en) New 1,4-diaminocyclitol derivatives, processes for their preparation and pharmaceutical compositions containing them
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.
AU8325191A (en) New phospholipid derivatives of nucleosides, their preparation and their use as antiviral drugs
ECSP993220A (es) Derivados de 3,3- biarilpiperidina y 2,2 - biarilmorfolina
RU94013118A (ru) Гетероциклические соединения и содержащие их фармацевтические соединения